BIOTECH WEEK IN JAPAN
SynapCell is proud to participate to BioJapan 2021, the leading partnering event for the biotech and life sciences industry in Asia.
Specialized in Central Nervous System, SynapCell contributes to discovering new treatments to cure brain diseases and strongly wishes to develop novel partnerships in Japan, backed by its long experience working with Japanese companies, that value the quality of work performed since 2005.
Let's meet online and discuss about our future project together !
SYNAPCELL APPOINTS DR. TATSUO MIYAUCHI TO SUSTAIN ITS MARKET DEVELOPMENT IN JAPAN
SynapCell was awarded a 3-years-perspective funding as part of the international development program of BPI France and Business France with the help of the cluster Lyonbiopole and La Région Auvergne Rhône Alpes.
This ambitious plan aims at providing SynapCell with significant resources to support its expansion in Japan and will strengthen its already established tight links with Japanese pharmaceutical companies, while building and developing new scientific collaborations in Japan.
The first milestone has already been achieved, with the arrival of a new experienced team member: Dr. Tatsuo MIYAUCHI, based in Yokohama, Japan.
Dr. Tatsuo MYAUCHI : a local Pharmacology and Drug development expert
Holding a PhD in Neuroscience, Dr. Miyauchi started his career as a faculty member in the Pharmacology Department of Tohoku University for 10 years. His major interest was the mechanism of action of antidepressants. He then moved to Chugai Pharmaceutical Co., Ltd as a CNS pharmacologist where he engaged in several drug discovery programs and built a significant track record in CNS research with over 40 scientific publications authored or co-authored.
After 10 years as a researcher, he then moved to the Research Management section. He then worked as a General Manager of Research division and supervised all of Chugai's Drug Discovery activities. In the meantime, he closely worked with electrophysiologists with several university research teams in Japan.
Thanks to its proven experience in preclinical pharmacology and extensive knowledge in current drug discovery challenges in Japan, Dr. Tatsuo Miyauchi now acts as a local Scientific Business Consultant to sustain SynapCell’s ambition to support Japanese Pharmaceuticals companies’ preclinical drug discovery journey, with the help of the translational power of EEG biomarkers.
Ton contact Dr Miyauchi, please reach out to him at firstname.lastname@example.org